RBC Bullish on Nuvation Bio as Safusidenib Delivers Durable Responses in Glioma with New Phase 3 and Phase 2 Studies

Nuvation Bio reports strong long-term Phase 2 data for safusidenib (52% ORR, 79% PFS) and announces new Phase 3 and Phase 2 studies in IDH1-mutant glioma.